473 related articles for article (PubMed ID: 23223143)
1. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
[TBL] [Abstract][Full Text] [Related]
2. Circulating melanoma cells as a predictive biomarker.
Karakousis G; Yang R; Xu X
J Invest Dermatol; 2013 Jun; 133(6):1460-2. PubMed ID: 23673501
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
6. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
Gray ES; Reid AL; Bowyer S; Calapre L; Siew K; Pearce R; Cowell L; Frank MH; Millward M; Ziman M
J Invest Dermatol; 2015 Aug; 135(8):2040-2048. PubMed ID: 25830652
[TBL] [Abstract][Full Text] [Related]
7. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
Li J; Fu W; Zhang W; Li P
Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.
Khoja L; Shenjere P; Hodgson C; Hodgetts J; Clack G; Hughes A; Lorigan P; Dive C
Melanoma Res; 2014 Feb; 24(1):40-6. PubMed ID: 24201293
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
11. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
14. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
15. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
16. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
17. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
18. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
20. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
